My ePortfolio Register   

Molecular testing for targeted therapies

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.05.17
Views: 1093

Prof Claus Garbe - University of Tübingen, Tübingen, Germany

Prof Garbe speaks with ecancer at EADO 2017 about targeted therapies for advanced and metastatic melanoma.

He describes the tremendous improvements in survival for metastatic disease treated with targeted therapy, from ~5% to ~40%, and considers how tumour evolution may expose ways to subvert treatment resistance with new druggable targets.

By combining multiple targets in combination or in sequence, Prof Garbe hopes for even greater survival improvements.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence